Trial Profile
A Multi -Center Randomized Parallel Group Comparative Active Controlled Safety Assessor Blinded Phase 3a Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agents of a Neuromuscular Block Induced by Rocuronium or Vecuronium at Reappearance of T2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Neostigmine
- Indications Neuromuscular blockade
- Focus Registrational; Therapeutic Use
- Acronyms Aurora
- Sponsors Merck Sharp & Dohme Corp.
- 17 Dec 2015 Results published in Merck media release.
- 26 Sep 2014 New trial record